JANX
$14.05
Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms technology to treat patients with cancer.
Recent News
Janux Therapeutics, Inc. (JANX) Commences Patient Dosing of JANX011 in Autoimmune Trial
Janux Therapeutics Inc. (NASDAQ: JANX) is one of the best cancer stocks to invest in now. On February 17, Janux Therapeutics Inc. (NASDAQ:JANX) commenced patient dosing in the Phase 1 study of JANX011. The company has already dosed the first patient in the trial evaluating JANX011 for the treatment of autoimmune diseases. The candidate drug […]
Where is Janux Therapeutics (JANX) Headed According to Analysts?
Janux Therapeutics, Inc. (NASDAQ:JANX) is one of the best immunotherapy stocks to buy according to hedge funds. JonesTrading maintained a Buy rating on Janux Therapeutics, Inc. (NASDAQ:JANX) on January 23, setting a price target of $50.00. The rating update came after Janux Therapeutics, Inc. (NASDAQ:JANX) announced on January 22 a collaboration and exclusive worldwide license […]
Wall Street Thinks These 4 Biotech Stocks Will Double–At Least–This Year
Wall Street analysts are placing aggressive bets on four clinical-stage biotech companies, with consensus price targets implying gains of up to 384%. These pre-revenue or early-revenue firms carry significant risk, but their late-stage pipelines and upcoming catalysts have convinced institutional investors to build substantial positions. All four trade with unanimous or near-unanimous Buy ratings, a ... Wall Street Thinks These 4 Biotech Stocks Will Double–At Least–This Year
Bristol Myers Squibb Expands RNA And Cell Therapy Pipeline As Valuation Lags
Bristol-Myers Squibb (NYSE:BMY) is acquiring Orbital Therapeutics in a $1.5b deal to expand its next generation RNA therapy capabilities. The company has entered a new commercial manufacturing agreement for its CAR T cell therapy programmes. Bristol-Myers Squibb also signed a new collaboration and license agreement with Janux Therapeutics focused on a solid tumor therapy. For investors watching NYSE:BMY at a share price of $57.62, these deals come as the company looks to refresh its...
Wall Street Analysts See a 319.23% Upside in Janux Therapeutics (JANX): Can the Stock Really Move This High?
The average of price targets set by Wall Street analysts indicates a potential upside of 319.2% in Janux Therapeutics (JANX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.